OR WAIT 15 SECS
Bayer and Dewpoint Therapeutics have announced an option, research, and license agreement aimed at developing novel treatments for cardiovascular and gynecological diseases.
Bayer and Dewpoint Therapeutics have announced an option, research, and license agreement aimed at developing novel treatments for cardiovascular and gynecological diseases, according to a Nov. 14, 2019 press release.
The companies will collaborate on the project, leveraging Dewpoint’s proprietary platform for biomolecular condensates and Bayer’s small-molecule compound library to develop new therapies. The agreement is reported to be worth up to US $100 million.
“As we continue to broaden our capabilities in R&D, the collaboration with Dewpoint gives us access to breakthrough innovation potential,” said Dr. Joerg Moeller, member of the executive committee of Bayer AG's Pharmaceuticals Division and head of Research and Development, in the press release. “New analytic tools and a growing understanding of biomolecular condensates could provide new insights into cellular functions that previously have not been considered by scientists in drug development, enabling us to identify novel pharmacological targets for future therapies.”
“This partnership is an exciting opportunity to advance treatments for diseases that have long evaded the industry. We look forward to combining Bayer's expertise in chemistry and drug development and Dewpoint's novel platform and insights into the role of biomolecular condensates in disease,” added Amir Nashat, CEO of Dewpoint. “We also look forward to working closely with Bayer to expand our capabilities in Germany and put the local biotech ecosystem at the forefront of this important and emerging area.”